ci 922 has been researched along with calcimycin in 1 studies
| Studies (ci 922) | Trials (ci 922) | Recent Studies (post-2010) (ci 922) | Studies (calcimycin) | Trials (calcimycin) | Recent Studies (post-2010) (calcimycin) |
|---|---|---|---|---|---|
| 9 | 0 | 0 | 11,946 | 40 | 444 |
| Protein | Taxonomy | ci 922 (IC50) | calcimycin (IC50) |
|---|---|---|---|
| XBP1 | Homo sapiens (human) | 1.41 | |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | 0.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boctor, AM; Pugsley, TA | 1 |
1 other study(ies) available for ci 922 and calcimycin
| Article | Year |
|---|---|
Effect of CI-922, a potential new antiallergy agent, on arachidonic acid metabolism in vitro.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Adult; Animals; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Arachidonic Acids; Azoles; Calcimycin; Cattle; Histamine Release; Humans; Hydroxyeicosatetraenoic Acids; In Vitro Techniques; Indoles; Indomethacin; Leukocytes; Male; Masoprocol; Pyrazoles; Seminal Vesicles; Tetrazoles | 1986 |